Literature Evidence and Arrive Assessment on Neuroprotective Effects of Flavonols Quercetin, Rutin and Isoquercitrin in Neurodegenerative Diseases’ Models

By Ana Carolina Bombardi Duarte, Maycon Giovani Santanai, Gulhermedi Camilo Orfalii, Carlos Tadeu Parisi de Oliveira & Denise Gonçalves Priolli

Sao Francisco University

Abstract- This paper was based on a literature search of PubMed and Scielo databases using the keywords “Flavonoids, Neuroprotection, Quercetin, Rutin, Isoquercitrin, Alzheimer, Parkinson, Huntington” and combinations of all the words. We collected relevant publications, during the period of 2000 to 2016, emphasizing in vivo and in vitro studies with neurological assessment of flavonol’s potentials, as well as classifying studies according to evidence levels, in order to elucidate evidence-based literature and its application on clinical research. In addition, we highlight the importance of flavonols in modern research fields, indicating their neuroprotective potential and use thereof as preventive and therapeutic treatment of numerous neurodegenerative disease. Neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, represent worldwide a major health problem with great financial impact. They are multifactorial diseases, hallmarked by similar pathogenesis that covers conditions such as oxidative stress, formation of free radicals, abnormal protein dynamics (degradation and aggregation), mitochondrial dysfunction, lipid peroxidation and cellular death or senescence. Flavonols are polyphenolic compounds, widely distributed in the plant kingdom and found in high concentrations in vegetables, fruits and teas. Their neuroprotective effects are mainly related to their antioxidant, anti-proliferative and anti-inflammatory properties. It was this paper’s intention to contribute with an evidence analysis of recent studies approaching neuroprotective effects of flavonols and the potential to conduct human clinical studies.

GJMR A Classification: NLMC Code: WL 140

Strictly as per the compliance and regulations of:
Literature Evidence and Arrive Assessment on Neuroprotective Effects of Flavonols Quercetin, Rutin and Isoquercitrin in Neurodegenerative Diseases’ Models

Ana Carolina Bombardi Duarte a, Maycon Giovani Santana b, Gulhermedi Camilo Orfali c, Carlos Tadeu Parisi de Oliveira d & Denise Gonçalves Priolli e

Abstract- This paper was based on a literature search of PubMed and Scielo databases using the keywords “Flavonoids, Neuroprotection, Quercetin, Rutin, Isoquercitrin, Alzheimer, Parkinson, Huntington” and combinations of all the words. We collected relevant publications, during the period of 2000 to 2016, emphasizing in vitro and in vivo studies with neurological assessment of flavonol’s potentials, as well as classifying studies according to evidence levels, in order to elucidate evidence-based literature and its application on clinical research. In addition, we highlight the importance of flavonols in modern research fields, indicating their neuroprotective potential and use thereof as preventive and therapeutic treatment of numerous neurodegenerative disease. Neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, represent worldwide a major health problem with great financial impact. They are multifactorial diseases, hallmarked by similar pathogenesis that covers conditions such as oxidative stress, formation of free radicals, abnormal protein dynamics (degradation and aggregation), mitochondrial dysfunction, lipid peroxidation and cellular death or senescence. Flavonols are polyphenolic compounds, widely distributed in the plant kingdom and found in high concentrations in vegetables, fruits and teas. Their neuroprotective effects are mainly related to their antioxidant, anti-proliferative and anti-inflammatory properties. It was this paper’s intention to contribute with an evidence analysis of recent studies approaching neuroprotective effects of flavonols and the potential to conduct human clinical studies.

1. Introduction

Flavonoids represent one of major polyphenolic groups, which are widely distributed in the plant kingdom and commonly found in vegetables, fruits and teas of the human diet. These compounds have shown low toxicity as well as a variety of physiological effects. In the past few decades, these naturally occurring compounds have attracted much attention by reported beneficial effects on health, such as antioxidant, antitumor, anti-inflammatory and anti-allergic effects, as well as presenting low toxicity to human organism. In midst the various classes of flavonoids, the flavonols have been the focus of many in vitro and in vivo studies for their diversified actions on numerous biological pathways. Structurally, flavonoids are composed of a basic flavylum cation, with three phenolic rings. Flavonols present subtle molecular changes to the main ring (Ring C), with the addition of a hydroxyl group (OH) on the third carbon, and a carbonyl group (C=O) on carbon fourth. Many reports have shown that structure changes of flavonoid molecules result in variations of bioavailability, by changing absorption efficiency and pathways; thus, also altering biological effects and creating action mechanisms specificity.

Flavonoids neuroprotective effects are mostly bound to its related antioxidant, anti-proliferative and anti-inflammatory properties. The Central Nervous System (CNS) is highly exposed to oxidative damage, due to high oxygen consumption, high levels of unsaturated lipids and presence of transitional metals. In addition, because of inefficient antioxidant defense mechanisms, alterations of neuronal organic homeostasis can cause grave repercussions. Antioxidant properties are correlated since oxidative stress and lipid peroxidation have been linked to a range of neurological pathologies, such as brain trauma, ischemia and neurodegenerative disorders. Thus, flavonoids ability to scavenge ROS and inhibit lipid peroxidation, protecting neuronal cells from oxidative damage, may be used to prevent and treat neurological pathologies. Neurodegenerative disorders, such as Alzheimer, Parkinson’s and Huntington’s disease cause a progressive functional alteration of neuronal systems. Worldwide, they present variable incidence and constantly relate to high morbidity rates, higher cost in health care and social impairment. These pathologies have been well studied; however, new advances in physiopathology and, therefore, in therapeutic modalities are infrequent, maintaining no cure or reversible treatments.

Author a: Scientific Initiation Program, Sao Francisco University Medical School, e-mail: carolbd92@hotmail.com
Author b: Postgraduate Program in Health Science, Sao Francisco University Medical School, Sao Paulo 12916-900, Brazil.
Other flavonoids, such as resveratrol, fisetin and hyperin have also been considered as potential drugs with neuroprotective effects. Recent studies verified, different flavonoids act on specific organic pathways, yet comparable studies between flavonoids are rare. Resveratrol, as an example, has shown neurological and cognitive enhancement properties in a clinical trial. Quercetin and rutin have been widely investigated as therapeutic drugs, especially concerning anti-proliferative and antioxidant effects, for many diseases, including CNS pathologies. However, neuroprotective potential of flavonoids in human trials has been poorly addressed, and Isoquercitrin has rarely been implied in studies investigating neuroprotective effects and comparison studies of the same subject.

II. Methods/Research

a) Literature Review

This paper was based on a literature search of PubMed and Scielo databases using keyword combinations "Flavonoids+Neuroprotection"; "Quercetin OR Rutin OR Isoquercitrin + Neuroprotection"; "Quercetin OR Rutin OR Isoquercitrin + Alzheimer OR Parkinson OR Huntington", during the period of 2000 to 2016. Clinical trials were assessed in each search. Studies involving flavonoid panel and flavonoid combinations were considered.

b) Literature Evidence

Evidence Based Medicine (EBM) is a systematic analysis of present-day research and scientific findings, in which obtained information is classified by authenticity and Evidence Level results.

<table>
<thead>
<tr>
<th>LEVEL</th>
<th>THERAPY</th>
</tr>
</thead>
<tbody>
<tr>
<td>1A</td>
<td>Systematic Reviews of Randomized Controlled Trials (RCT)</td>
</tr>
<tr>
<td>1B</td>
<td>Individual RCT with narrow Confidence Interval</td>
</tr>
<tr>
<td>1C</td>
<td>All or None Studies</td>
</tr>
<tr>
<td>1D*</td>
<td>In Vivo Animal Trials</td>
</tr>
<tr>
<td>2A</td>
<td>Systematic Reviews of Cohort Studies</td>
</tr>
<tr>
<td>2B*</td>
<td>I. Cohort Studies (In Human)</td>
</tr>
<tr>
<td></td>
<td>II. Ex Vivo Studies</td>
</tr>
<tr>
<td>2C*</td>
<td>Outcome Research or Ecological Studies or In Vitro Studies</td>
</tr>
<tr>
<td>3A</td>
<td>Systematic Review of Case-Control Studies</td>
</tr>
<tr>
<td>3B*</td>
<td>Case-Control Studies or Drug Biological Characteristics Assessment Studies</td>
</tr>
<tr>
<td>4*</td>
<td>Case-series and poor quality cohort and case-control studies or Literature Review</td>
</tr>
<tr>
<td>5</td>
<td>Expert opinion without explicit critical appraisal</td>
</tr>
</tbody>
</table>

*Modified items from Oxford CEBM

Table 1: Evidence Level adapted from Oxford CEBM to evaluate therapeutic value of scientific studies.

Thus creating a hierarchy system to evaluate information and incorporate in a practical environment of research, as well as to support the conduct of clinical care and therapeutic options. Recommendation levels are the results of extensive research analysis and an important guide to practitioner’s clinical decisions. Although animal experiments have always contributed to our understanding of drug action mechanisms and pathophysiological aspects of many diseases, some authors debate on whether animal researches are valuable predictors of human conditions and pathogenesis, due to interspecies differences and lack of uniform requirements for reporting animal data and comparable results. Considering the pyramid of medical research, animal experimentation and in vitro studies take their place at the bottom, reflecting basic studies; however, tools of assessment of these studies have emerged in the last decade to improve transparency and accuracy of reports. One of which, ARRIVE guidelines (Animals in Research: Reporting in Vivo Experiments) creates a checklist of 20 steps to be met during animal experimentation reports. Although ARRIVE checklist is not mentioned in many animal reports, in the past five years endorsement of this tool amongst journals has risen considerably, becoming an important source of evaluation. Thus, it was this paper’s intent to grade Animal Experimentation and In Vitro Studies’ Evidence Level, through a personal classification (Table 1), derived from the Oxford Centre for Evidence Based Medicine (CEBM). In addition, apply the ARRIVE checklist to In vivo animal studies referenced in this paper.

c) Flavonoids

Flavonoids represent one of major polyphenolic groups, which are widely distributed in the plant kingdom and commonly found in vegetables, fruits and teas of the human diet. Recent experimental studies and clinical trials conducted with flavonoids, in particular the class of flavonols, have demonstrated a wide variety of physiological effects, including antioxidant, anti-proliferative/antitumor and anti-inflammatory, also correlating some of their action mechanisms to neuroprotective potential. Thus evidencing this class of molecules as an accessible alternative of preventive...
therapy or treatment of numerous neurological diseases. Flavonoids can be found in nature as aglycone forms, glycosides or methylated/acylated derivatives. Amongst flavonoid representatives, the best-known molecules are (1) Quercetin, an important aglycone form and a pioneer subject mid flavonoid research; (2) Rutin, main hydrophilic glycoside molecule; and (3) Isoquercitrin (IQ), main lipophilic glycoside, also known as quercetin-3-O-glucoside (Q3G) and Isoquercetin, a nearly identical hydrophilic glycoside molecule; and (3) Isoquercitrin, a nearly identical hydrophilic glycoside molecule. Flavonoids absorption occur predominantly in the small intestine, however it is limited by molecular weight and hydrophilicity. Few studies have been conducted as to elucidate bioavailability and absorption across the blood-brain barrier in human models (Evidence Level 1B), whereas most studies have used in vivo animal models, biological differences and lack of complete physiological understanding of flavonoid’s absorption in the small intestine, have limited new findings. Nevertheless, the type of sugar moiety attached to primary aglycone molecule, has been named the major determinant of small intestine absorption, rather than its position in the same molecule.

In food plants, quercetin occurs almost exclusively as glycosides, in which the and the dominant type of glycoside vary amongst foods and is usually located at the 3 or 4 position of the pyrone ring. Onions, kale, broccoli and apples are important sources of glycoside molecules, such as Rutin. IQ is a common naturally occurring glycoside also obtained by enzymatic hydrolysis of rutin with hesperidinase, an enzyme produced by specific types of fungi such as Penicillium sp.

Hesperidin has a α-L-rhamnosidase selective activity when applied at 58°C for 30 minutes, capable of cleaving the rhamnosidase radical of rutin’s basic structure and leaving the glycoside radical intact, transforming it into IQ. This procedure, generates what is called enzymatic modified IQ or Hydrolysed Rutin (HR), both of which consists of a mixture that includes IQ (69.5%), quercetin (7.5%), rutin and other small metabolites. Studies have shown the superiority of anti-oxidant and anti-proliferative properties of HR when compared solely to quercetin and rutin (Evidence Level 2C).

III. Neurodegenerative Diseases

Neurodegenerative diseases are a consequence of genetic and environmental factors that are strongly associated with age. These disorders arise from multifactorial conditions that interfere directly with cellular oxidative homeostasis and function. Amongst various pathophysiological factors, increased oxidative stress, mitochondrial dysfunction and abnormal protein dynamics represent a common role in the development of different neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS). Also appearing to command numerous neuronal pathways, leading to alterations in neurotransmission and ion channels, protein aggregation, impaired bioenergetics and even cellular death.

Free radicals are indispensable molecules to cellular function by involvement in many biochemical activities. However, oxidative stress arise from disturbances between pro-oxidant/antioxidant equilibrium. Overproduction of free radicals produces cytotoxicity and genotoxicity by damaging biomolecules, such as proteins, lipids and DNA and leading to arise of various chronic diseases, including in the CNS. In the brain glial and neuronal cells are particularly sensitive to free radicals and actively targeted by ROS. Primary neuroprotective potential of flavonoids rely mainly on their antioxidant effect and leading mechanism of action seems to be reduction of cellular oxidative stress by scavenging and decreasing reactive oxygen species (ROS) and reactive nitrogen species (RNS) in brain tissue (Evidence Level 2C).

Flavonoids exhibit anti-oxidant enzymes (Evidence Level 1B), protein disaggregation and diminished production (Evidence Level 2C), decrease of lipid peroxidation (Evidence Level 1B), transitional metal chelation (Evidence Level 2C) and anti-inflammation effects (Evidence Level 1B). Although, Ansari et al. (2009) demonstrated in an in vitro study that quercetin showed dual effect on oxidative stress; at lower dosages, antioxidative effects were observed, though in higher dosages, it exhibited a pro-oxidant effect also increasing neuronal dysfunction, it is still clear flavonoids present oxidative-protective effects on various diseases, including those of the CNS.

a) Alzheimer’s Disease

Alzheimer’s disease (AD) is a complex neurological disorder clinically characterized by progressive loss of memory and cognition; histopathology demonstrates accumulation of extracellular β-amyloid plaques (major constituent of senile plaques), intracellular neurofibrillary tangles, tau protein phosphorylation and neurodegeneration of synaptic neurons, especially in the hippocampus. Oxidative stress and neuro-inflammation are also considered hallmarks of AD, mainly responsible for increased neurotoxicity of cognitive-modulating areas. In addition, the decrease in cholinergic neurotransmission has also been implicated in cognitive decline and behavioral changes of AD.

Flavonoids represent an interesting class of phytochemicals and, even before scientific studies, have
been widely used as phytotherapy medicines, like Ginkgo biloba, which includes quercetin and kaempferol. In 2009, Shi et al. demonstrated quercetin molecule was responsible for high antioxidant activity of this plant extract, corroborating to the hypothesis of flavonoids, in particular flavonols, as possible therapeutic drugs with neuroprotective potential (Evidence Level 2C). A main pathophysiological mechanism of AD is the transformation of β-amyloid peptides into amyloid-beta (Abeta) plaques and the extracellular aggregation of plaques in areas such as the hippocampus, which appear to be an early phenomenon and is currently used as a diagnostic tool of the disease through PET scan markers (Evidence Level 2A). In the last few years, some studies have comprised flavonoid’s neuroprotective potential and investigated anti-amyloidogenic properties. Ansari et al. (2009) demonstrated quercetin’s protective effect under low dosages (5 μM and 10 μM), strongly inhibiting Abeta fibril formation and preventing glutathione oxidation (Evidence Level 2C). In 2011, Jimenez-Aliaga evaluated anti-amyloidogenic potential of both quercetin and rutin, demonstrating inhibition of Abeta fibrils formation and disaggregation by both compounds, however, noticing statistical superiority of quercetin’s effects. Also reporting the reduction of ROS production and lipid peroxidation index (Evidence Level 2C). In addition, Choi et al. (2014) studied their in vitro activity of a flavonoid panel, including quercetin and rutin, against Abeta-induced toxicity. Results corroborated previous studies showing that flavonoids significantly block Aβ-induced neuronal toxicity (Evidence Level 2C).

Liu et al., 2013 investigated in vivo the protective effects of quercetin against Abeta-induced toxicity, on both endothelial cells and neurons, after oral administration of quercetin for a period of 8 days; learning and memory were evaluated by Morris Water Maze test, and cerebral flow was closely monitored. Results showed neurovascular coupling protection, with reduction of oxidative stress and maintenance of neurovascular unit (Evidence Level 1D).

Recent in vitro and in vivo studies investigated neuroprotective effects of quercetin on Abeta-induced toxicity models. Results showed quercetin improved cell viability, by diminishing neuronal and endothelial oxidative stress (Evidence Levels 2C, 1D) and the production of ROS and LDH were decreased, as an increase on superoxide dismutase occurred (Evidence Level 2C). Mohebali et al., 2016 demonstrated both Rutin’s and Quercetin’s potential to down regulate inflammation-involved genes in AD (Evidence Level 1D). Moreover, Sabogal- Guáqueta et al., performed an in vivo study with quercetin (25mg/kg) i.p. administration, for 3 months, on triple transgenic AD model mice, observing a decrease of extracellular β-amyloid deposition, as well as a reduction of tau phosphorylation, astrogliaosis and microgliaosis in the hippocampus and amygdala (Evidence Level 1D).

Isolated, rutin has been less studied in AD over the years. In 2012, Javed et al. conducted the investigation of rutin’s neuroprotective antioxidant effects in an in vivo intracerebroventricular-streptozotocin (ICV-STZ) induced toxicity model. Rutin was pre-administered orally (25mg/kg) for 3 weeks, and results indicated attenuation of STZ-induced inflammation by reducing the expression of cyclooxygenase-2 (COX-2), interleukin-8 (IL-8) and nuclear factor-kB, thus preventing neuro-inflammatory morphological changes in the hippocampus (Evidence Level 1D).

In addition, recent studies that comprised rutin’s antioxidant activity on Abeta-induced neurotoxicity showed the decrease of ROS and RNS as the main action mechanism, consequently reducing lipid peroxidation. Interestingly, rutin was also capable of diminishing glutathione levels and dependent enzymes, also downregulating astrocytosis and microgliosis and, therefore, proving to having similar effects to quercetin (Evidence Levels 1D).

Another hallmark characteristic of AD is the decrease in cholinergic neurotransmission, which has been implicated in cognitive decline, leading to dementia, and behavioral disorders. The increase on cholinergic neurotransmission is an important focus of recent drug therapy and comprises the inhibition of acetylcholinesterase (AchE), acetylcholine’s degrading enzyme. Both quercetin and rutin have been targets of recent studies focusing on AchE inhibition, since it is an important target on Alzheimer’s drug therapy. Quercetin is a strong AchE inhibitor (Evidence Levels 1D, 2B) presenting higher binding strength to active site of the enzyme than some of the drugs in the market, like Donezepil, also acting in a dose-dependent manner (Evidence Level 3B). Rutin also seems to show AchE inhibition properties (Evidence Level 3B), however no study has solely involved this compound. There are no studies indexed on PubMed or Scielo involving isoquercitrin’s specific neuroprotective effects in AD. Nevertheless, IQ exhibits important antioxidant activity and has been implied as a promising molecule for the treatment of several pathologies, especially cancer.

b) Parkinson’s Disease

Parkinson’s disease (PD) is a neurodegenerative movement disorder mainly characterized by progressive loss of dopaminergic neurons within nigrostriatal pathway, affecting substantia nigra area, and associated with microglial-mediated neuro-inflammation. Pathogenic aspects of PD involve mitochondrial dysfunction, changes in micro-RNA and α-synuclein levels, a major constituent of Lewy bodies and a hallmark of PD. Oxidative stress has been
associated as a risk factor for dopamine cellular degeneration of PD⁹³, and mitochondrial dysfunction plays an important role on energetic balance as well as regulating oxidative and apoptotic pathways³⁸.

Quercetin has been widely investigated for its antioxidant effects; however, specific PD model investigations are scarce. On chronic rotenone (ROT)-induced parkinsonian models quercetin (25-75mg/kg i.p.) showed reduced loss of ROT-induced dopaminergic neurons, also decreasing glutathione levels and increasing anti-oxidant enzymes (catalase and superoxide dismutase)⁶⁰. In 2015, Denny Joseph et al., also investigated on ROT-induced models the beneficial effects of treatment association between fish oil and quercetin. Results corroborated previous studies demonstrating significant behavioral change as well as attenuation of oxidative stress and mitochondrial dysfunction indicators (Evidence Level 1D)⁸¹.

Other studies using methyl-4-phenylpyridinium ion (MPP(+) ), a parkinsonian toxin that provokes degeneration of dopaminergic neurons⁶⁰, and 6-hydroxydopamine (6-OHDA), a selective dopaminergic neurotoxin⁶⁰. Also demonstrated quercetin’s neuroprotective potential by reducing apoptotic neuronal death, through modulation of pro-apoptotic (Bax) and anti-apoptotic (Bcl-2) genes, and decreasing oxidative stress and neuro-inflammation (IL-1, TNF-α and COX-2) on microglial cells (Evidence Levels 2C, 2C, 1D, 1D)⁸²-⁸⁸. Although these results are consistent with literary review appointing quercetin as an antioxidant molecule, some studies have shown a paradoxical effect of this compound when used in high dosages (Evidence Level 2C)⁸⁹.

In addition, in 2015, Ahn et al. investigated quercetin’s specific effect on α-synuclein expression. During the experiment, PC12 cells were pre-treated with quercetin and results showed quercetin presents neuroprotective effects affecting various mechanisms such as apoptosis and oxidative stress; however, quercetin treatment increased α-synuclein levels, and although cell viability and survival were unaltered with the up-expression, this data suggests quercetin’s effects on PD is still not entirely understood (Evidence Level 2C)⁸⁸.

During the course of 2014 to 2016, Magalingam et al., produced a series of three articles investigating Rutin and Isoquercitrin on 6-OHDA PD-induced models. Both rutin and IQ demonstrated antioxidant effects by reducing lipid peroxidation and increasing anti-oxidant enzymes (catalase, superoxide dismutase and glutathione peroxidase) (Evidence Level 2C)⁸⁶-⁸⁸. Cytoprotective activity of IQ occurred in a dose-dependent manner. Furthermore, Rutin showed upregulation of the TH gene, an important factor in dopamine biosynthesis; as well as modulation of apoptotic pathways by reducing Park2, Park5, Park7, Caspase 3 and Caspase 7 genes (Evidence Level 2C)⁸⁶.

c) Huntington’s Disease

Huntington’s disease (HD) is an autosomal dominant, progressive, neurodegenerative disorder clinically characterized by motor, cognitive and behavioral impairment, also presenting high morbidity and mortality rates⁹⁰. Incidence is higher at European countries and mean age of symptoms onset occurs around 40 years old⁹⁰. HD is cause by an expanded CAG trinucleotide repeat in the HTT gene, responsible for encoding the protein huntingtin. The mutation lead to the production of an abnormal protein with long polyglutamine sequences that confers toxic properties and predisposes protein fragmentation, which can result in neuronal death⁹¹.

Quercetin is the only major flavonol whose neuroprotective effect has been associated to Huntington’s disease treatment potential. In this review, we found no articles investigating rutin or isoquercitrin effects on HD models. In 2013, Sandhir et al., evaluated oral supplementation of quercetin (25mg/kg) on 3-nitropropionic acid-induced (3-NP) Huntington’s disease animal model. Posterior analysis was conducted on mitochondrial biogenetics, oxidative stress, neurobiological behaviors and histopathological assays. It was proven quercetin exhibits protective effects by attenuating mitochondrial oxidative stress (reduced lipid peroxidation and mitochondrial swelling), as well as increasing motor skills and antioxidant elements (Evidence Level 2B)⁹². Additionally, in 2014, quercetin was once again tested on 3-NP-induced HD models, confirming previous results of antioxidant properties and motor coordination increase, along with display of behavioral changes throughlessening of anxiety and isolation; also reducing neuro-inflammatory responses with an increase of astrocyte numbers in core lesions and decreased microglial proliferation (Evidence Level 1D)⁹³,⁹⁴.
Flavonoids have been widely investigated in the past decades and have shown a wide variety of physiological effects, determining a therapeutic potential on innumerable diseases, including neurological pathologies. Their neuroprotective effects are mostly related to anti-oxidant and anti-inflammatory properties; however, specific mechanisms have been reached on in vitro studies conducted with flavonols are order to foresee favorable outcomes, and although most animal experimentation references seem to in vivo studies are still the majority of literature references, and animal experiments, due to its superiority of anti-oxidant and anti-proliferative properties.

### IV. Conclusion

References Références Referencias


### Table 2: ARRIVE Checklist evaluation of in vivo Animal Studies referenced

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Flavonoid Tested</th>
<th>ARRIVE Checklist Items Met</th>
<th>ARRIVE Checklist Items Not-Met</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liu et al.</td>
<td>2013</td>
<td>Quercetin</td>
<td>1-9, 10a, 11b, 12-20</td>
<td>10b, 11a</td>
</tr>
<tr>
<td>Hayakawa et al.</td>
<td>2015</td>
<td>Quercetin</td>
<td>1,2,3a, 4-9, 11-13, 15-20</td>
<td>3b, 10, 14</td>
</tr>
<tr>
<td>Sabogal-Guajeda et al.</td>
<td>2015</td>
<td>Quercetin</td>
<td>1,2,3a, 4-8,11b, 12,13, 16-20</td>
<td>3b, 8a, 10, 11a, 14,15</td>
</tr>
<tr>
<td>Javed et al.</td>
<td>2012</td>
<td>Rutin</td>
<td>1, 2, 3a, 4-9, 10a, 12, 13, 15-20</td>
<td>3b, 10b, 10c, 11, 14</td>
</tr>
<tr>
<td>Choi et al.</td>
<td>2015</td>
<td>Rutin</td>
<td>1-9, 10a, 11-20</td>
<td>10b, 10c</td>
</tr>
<tr>
<td>Xu et al.</td>
<td>2014</td>
<td>Rutin</td>
<td>1, 2, 3a, 4-9, 10a, 11-13, 15-20</td>
<td>3b, 10b, 10c, 14</td>
</tr>
<tr>
<td>Moghbelinejad et al.</td>
<td>2014</td>
<td>Rutin</td>
<td>1,2,3a, 4, 5, 6a, 6c, 7, 8b, 9, 12, 13, 15-20</td>
<td>3b, 6b, 8a, 10, 11, 14</td>
</tr>
<tr>
<td>Abdalla et al.</td>
<td>2014</td>
<td>Quercetin</td>
<td>1-9, 10a, 11-19</td>
<td>10b, 10c, 20</td>
</tr>
<tr>
<td>Karuppagounder et al.</td>
<td>2013</td>
<td>Quercetin</td>
<td>1-9, 12-14, 16, 17-20</td>
<td>10, 11, 15</td>
</tr>
<tr>
<td>Zhang et al.</td>
<td>2011</td>
<td>Quercetin</td>
<td>1-5, 8, 10, 12-14, 16-20</td>
<td>6, 7, 9, 11, 15</td>
</tr>
<tr>
<td>Haleagrahara et al.</td>
<td>2013</td>
<td>Quercetin</td>
<td>1-20</td>
<td>-</td>
</tr>
<tr>
<td>Jain et al.</td>
<td>2014</td>
<td>Quercetin</td>
<td>1-2, 3a, 4-20</td>
<td>3b</td>
</tr>
<tr>
<td>Chakraborty et al.</td>
<td>2014</td>
<td>Quercetin</td>
<td>1-5, 6a, 6b, 7-10, 12-14, 16-20</td>
<td>6c, 11, 15</td>
</tr>
</tbody>
</table>


28. Pound P, Bracken MB. Is animal research sufficiently evidence based to be a cornerstone of biomedical research? BMJ. 2014; 348 (may30 1): g3387-g3387. doi:10.1136/bmj.g3387.


33. Cialdella-Kam L, Nieman DC, Sha W, Meaney MP, Knab AM, Shanelly RA. Dose-response to 3 months...


37. Jung SH, Kim BJ, Lee EH, Osborne NN. Isoquercitrin is the most effective antioxidant in the plant Thuja orientalis and able to counteract oxidative-induced damage to a transformed cell line (RGC-5 cells). Neurochem Int. 2010; 57(7): 713-721. doi:10.1016/j.neuint.2010.08.005.


